First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British journal of …, 2014 - nature.com
… open-label, phase-IV, follow-up study of efficacy, safety and tolerability of gefitinib in Caucasian
patients with EGFR mutation-… (plasma) for EGFR mutation analysis and assess whether …
patients with EGFR mutation-… (plasma) for EGFR mutation analysis and assess whether …
… gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
… Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon …
Randomisation, stratified by EGFR mutation type and status of brain metastases, was done …
Randomisation, stratified by EGFR mutation type and status of brain metastases, was done …
… first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
… Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR
mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR …
mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
… patients with EGFR mutation-positive NSCLC. This prospective, phase II, open-label study
(… the first-line setting for Japanese patients with EGFR mutation-positive NSCLC, in order to …
(… the first-line setting for Japanese patients with EGFR mutation-positive NSCLC, in order to …
… treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
… date is EGFR mutation status; recent data suggest that patients with tumours that harbour
activating mutations in EGFR (ie, exon 19 deletions or exon 21 L858R point mutations) achieve …
activating mutations in EGFR (ie, exon 19 deletions or exon 21 L858R point mutations) achieve …
[HTML][HTML] … gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label …
… Epidermal growth factor receptor (EGFR) is critical in proliferation and survival pathways,
and activating mutations are often seen in NSCLC [2]. EGFR mutations occur more frequently …
and activating mutations are often seen in NSCLC [2]. EGFR mutations occur more frequently …
… versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa… - The Lancet …, 2017 - thelancet.com
… -type EGFR or unknown EGFR mutation status had a shorter progression-free survival and
fewer objective responses. We searched PubMed using the search string “(EGFR AND lung …
fewer objective responses. We searched PubMed using the search string “(EGFR AND lung …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The lancet …, 2016 - thelancet.com
… Patients were required to have documented evidence of EGFR tyrosine-kinase inhibitor
sensitising mutations. EGFR Thr790Met status and other EGFR mutations were centrally …
sensitising mutations. EGFR Thr790Met status and other EGFR mutations were centrally …
[HTML][HTML] Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
… However, the importance of EGFR mutations in pancreatic cancer has not been investigated
until now. The EGFR mutation profile in the Chinese population analyzed in this study can …
until now. The EGFR mutation profile in the Chinese population analyzed in this study can …
… for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
相关搜索
- multicentre open label
- egfr mutations small cell lung cancer
- egfr mutations international multicentre single arm
- randomized open label
- open label first line gefitinib
- open label gemcitabine cisplatin in patients
- egfr mutation randomised open label
- egfr mutation phase 3 randomised trial
- egfr mutation first line treatment
- egfr mutations combined survival analysis
- egfr mutations first line gefitinib
- egfr mutations prospective clinical trials
- egfr mutations pemetrexed in japanese patients
- egfr mutations cisplatin plus pemetrexed
- open label single arm study
- open label nsclc patients